Methods for increasing oral osteogenesis using lipoxin A4 (LXA4) and its analogs
The invention provides methods for increasing oral osteogenesis using LXA 4 and its analogs. Methods are also provided for treating or preventing oral disorders that would benefit from increased oral osteogenesis using LXA 4 and its analogs.
1. A method of increasing oral osteogenesis in a subject afflicted with a periodontal disease comprising:
a) performing periodontal flap surgery upon at least one periodontal lesion of the subject; and
b) topically administering a therapeutically effective amount of 9,12 benzo-LXA 4 to the surgical wound at the time of surgery, wherein the 9,12 benzo-LXA 4 is encapsulated in a nanoparticle, and wherein the effective amount of the 9,12 benzo-LXA 4 is an amount that increases oral osteogenesis by at least 10% relative to that of no treatment;
to thereby increase oral osteogenesis in the subject.
2. The method of claim 1 , wherein the periodontal disease is selected from the group consisting of periodontitis, gingivitis, chronic periodontitis, aggressive periodontitis, necrotizing periodontal disease, periodontium abscesses, and post-operative gingival infections.
3. The method of claim 1 , wherein the 9,12 benzo-LXA 4 is formulated in a pharmaceutically acceptable carrier.
4. The method of claim 3 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of gels, tooth pastes, dentifrice, buccal patch, dental fibre, and dental tape.
5. The method of claim 1 , further comprising the step of administering a therapeutically effective amount of 9,12 benzo-LXA 4 to the at least one periodontal lesion at least one time after periodontal flap surgery completion.
6. The method of claim 1 , further comprising administering at least one additional agent that treats the periodontal disease at least one time after periodontal flap surgery completion.
7. The method of claim 6 , wherein the additional agent is selected from the group consisting of anti-inflammatory agents and antimicrobial agents.
8. The method of claim 1 , wherein the 9,12 benzo-LXA 4 encapsulated in a nanoparticle is administered using an intraoral delivery device.
9. The method of claim 1 , wherein the nanoparticle is of biologic or synthetic origin.